Therapeutic insights into “awakening the sleeping/cancer-protecting angels” in mutant p53-expressing human tumors: PAPD5 (Poly(A) RNA Polymerase D5, Non-Canonical) increases the expression of tumor suppressor p53 homologue TA-p73/p63, PTEN, TPM1, TIMP3, BTG2, PDCD4, SPRY1/2 and CCM1/KRIT1 and induces regression of p53-mutated human tumors via down regulation of its target gene, 25/December/2016, 9.18 pm

Natural product-derived therapy for Human Leukemias: Boehmenan, found in stem of Caulis clematidis armandii and Hibiscus ficulneus, suppresses B-Cell and myeloid leukemias via up regulation of the tumor suppressor IRF4, 25/December/2016, 12.03 am
December 24, 2016
Natural product-derived therapy for enhancing anti-cancer immunity: Emodin (6-methyl-1,3,8-trihydroxy anthraquinone), found in Polygonum multiflorum, decreases the level of LATS1/2 (large tumor suppressor 1 and 2), increases immunogenicity of tumors, enhances anti-tumor immune responses, and inhibits tumor growth via down regulation of its target gene, 25/December/2016, 10.00 pm
December 25, 2016
Show all

From Significance of the study to Public health relevance:

Given that: (1) Cancer suppressor p53 is mutated in more than 50% of human cancers of different tissue origin; (2) p53 pathway is altered in about 80% of tumors.; (3) our understanding is incomplete in terms of molecular targets and the oncogenic/malignant pathways involved in mutant p53-overexpressing tumors; (4) cancer causes the highest economic loss compared to all the known causes of death worldwide; and (5) cancer causes the considerable economic loss worldwide, there is an urgent need to find: (i) a cheaper alternative to the existing expensive drugs; (ii) a side-effect-free natural product-based drug; and (iii) a way to effectively treat and stall metastatic progression and relapse of mutant p53-overexpressing human cancers.


From therapeutic strategy to Research Findings:

(i) Therapeutic strategy: 

This study suggests a therapeutic strategy for stalling the progression of p53-deficient/deleted or mutant-p53 expressing metastatic cancers. By activating tumor suppressor p53’s unmutated “homologous protein such as TAp73/p63” in p53-deficient or mutant-p53 expressing metastatic cancer cells, one can stall their progression.

(ii) Research findings:  

PAPD5 (Poly(A) RNA Polymerase D5, Non-Canonical), by decreasing the expression of its target genes, it may not only increase the expression of tumor suppressors genes, such as TAp73, TAp63, PTEN, etc., but also increase a number of metastatic suppressor genes, such as TPM1, TIMP3, BTG2, PDCD4, SPRY1/2, CCM1/KRIT1 etc. Thereby, it may inhibit the migration and invasion of metastatic cancer cells expressing mutant-p53 (figure1).

papd5-induces-the-expression-of-tap73-to-regress-mutant-p53-exp-tumors

Figure 1. Mechanistic insight into how PAPD5 functions as a tumor suppressor protein. PAPD5, by activating tumor suppressor genes, such as TAp73, TAp63, PTEN, PDCD4, BTG2, etc., and metastatic suppressor genes, such as TPM1, TIMP3, SPRY1/2 etc., in  metastatic tumors, it may inhibit the progression of mutant-p53 expressing human cancers.


Therapeutic opportunity:

Given the ability of PAPD5 to induce the expression of TAp73, TAp63, PTEN, TPM1, TIMP3, BTG2, PDCD4, SPRY1/2, CCM1/KRIT1, long ncRNA Gas5 in p53-mutated human tumors, pharmacological formulations encompassing PAPD5 activators or PAPD5 activators plus any of the known anticancer agents” may be used to inhibit the progression of p53-mutated invasive metastatic tumors.

price-100

Together, this study suggests a natural-product-based therapy for p53-mutated metastatic human tumors.[easy_payment currency=”USD”]


Details of the research findings

Idea Proposed/Formulated by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Amount: $100#

Undisclosed mechanistic information: How PAPD5 increases the expression of tumor suppressor genes (TAp73, TAp63, and PTEN); and  metastatic suppressor genes (TPM1, TIMP3, BTG2, PDCD4, SPRY1/2, CCM1/KRIT1, RECK) in mutant p53 expressing cancer cells?

For purchase and payment details, you may reach us at admin@genomediscovery.org

#Research cooperation


References:

Web: http://genomediscovery.org or http://newbioideas.com

Citation: Boominathan, L., Therapeutic insights into “awakening the sleeping/cancer-protecting angels” in mutant p53-expressing human tumors: PAPD5 (Poly(A) RNA Polymerase D5, Non-Canonical) increases the expression of tumor suppressor p53 homologue TA-p73/p63, PTEN, TPM1, TIMP3, BTG2, PDCD4, SPRY1/2 and CCM1/KRIT1 and induces regression of p53-mutated human tumors via down regulation of its target gene, 25/December/2016, 9.18 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at admin@genomediscovery.org

Comments are closed.